News

Published on 20 Jun 2024 on Simply Wall St. · via Yahoo Finance

Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx...

Article preview image

Key Insights

Ultragenyx Pharmaceutical will host its Annual General Meeting on 18th of JuneCEO Emil Kakkis' total compensation includes salary of US$823.7kThe total compensation is 56% higher than the average for the industry Ultragenyx Pharmaceutical's EPS declined by 22% over the past three years while total shareholder loss over the past three years was 54%

Read the rest of the article
NASDAQ.RARE price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this...

Insider Monkey · via Yahoo Finance 17 Jan 2025
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees...

In conjunction with the 2025 J.P. Morgan Healthcare Conference, the analyst hosted an investor lu...

Benzinga · via Yahoo Finance 15 Jan 2025
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust...

Ultragenyx Pharmaceutical Inc (RARE) reports a 42% year-over-year revenue increase, driven by str...

GuruFocus.com · via Yahoo Finance 6 Nov 2024
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarte...

Insider Monkey · via Yahoo Finance 1 Nov 2024
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks...

We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article,...

Insider Monkey · via Yahoo Finance 21 Aug 2024
Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx...

Key Insights Ultragenyx Pharmaceutical will host its Annual General Meeting on 18th of JuneCEO Em...

Simply Wall St. · via Yahoo Finance 20 Jun 2024
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

Ultragenyx Pharmaceutical RARE announced positive top-line results from the late-stage study of i...

Zacks via Yahoo Finance 31 May 2024
Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...

Total Revenue: Reported $109 million in Q1 2024, an 8% increase year-over-year, falling short of ...

GuruFocus.com via Yahoo Finance 5 May 2024
Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) just released its latest first-quarter report and th...

Simply Wall St. via Yahoo Finance 4 May 2024
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript May 2, 2024 Ultrage...

Insider Monkey via Yahoo Finance 4 May 2024

Copyright Statfolio @ 2025

Social Accounts